Loading clinical trials...
Loading clinical trials...
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Conditions
Interventions
PF-04965842
PF-04965842
+3 more
Locations
64
United States
Clinical Research Center of Alabama
Birmingham, Alabama, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
Huntington Medical Foundation
Pasadena, California, United States
Peninsula Research Associates, Inc.
Rolling Hills Estates, California, United States
Emil A. Tanghetti MD dba Center for Dermatology and Laser Surgery
Sacramento, California, United States
TCR Medical Corporation
San Diego, California, United States
Start Date
April 1, 2016
Primary Completion Date
March 1, 2017
Completion Date
April 1, 2017
Last Updated
May 2, 2019
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions